Al-Toubah T, et al. - Since ibrutinib restrains mast cell degranulation and has been correlated with the regression of tumors in a mouse insulinoma mode, the researchers evaluated the role of ibrutinib in various advanced neuroendocrine neoplasms (NENs) and evidence of activity in these patients. For this prospective, phase 2 trial, they assessed 20 patients with advanced GI/lung NENs and pancreatic NENs (pNENs) with evidence of progression within 12 months of entering the study on at least one previous therapy. Until unacceptable toxicity, disease progression, or withdrawal of consent, patients received ibrutinib 560 mg daily. In well-differentiated gastroenteropancreatic and lung NENs, ibrutinib does not demonstrate significant activity.